Genomic and Non-Genomic Effects of Aldosterone

Total Page:16

File Type:pdf, Size:1020Kb

Genomic and Non-Genomic Effects of Aldosterone 132 Current Signal Transduction Therapy, 2012, 7, 132-141 Genomic and Non-genomic Effects of Aldosterone Andrea Verhovez*, Tracy A. Williams, Silvia Monticone, Valentina Crudo, Jacopo Burrello, Maddalena Galmozzi, Michele Covella, Franco Veglio and Paolo Mulatero Department of Medicine and Experimental Oncology, Division of Internal Medicine and Hypertension, University of Torino, 10126 Torino, Italy Abstract: The last two decades have witnessed a growing number of experimental observations regarding the mineralocorticoid physiopathology, leading to a new understanding of the molecular basis of the aldosterone-induced target organ damage. As a matter of fact, although it has long been known that the combined administration of mineralocorticoids and salt leads to extensive vascular lesions in the target organs, the recognition that aldosterone is able to induce direct toxic effects on the various cell types that make up the cardiovascular organ has built up recently. Moreover, non-genomic effects have been attributed to aldosterone, i.e. effects which do not depend on the activation of the cellular transcription machinery, whose physiopathologic relevance is still being investigated. These advances in our understanding of aldosterone physiopathology have shed light on the biological reasons which are at the base of the impressive results obtained in clinical trials of aldosterone antagonism. Keywords: Aldosterone, hyperaldosteronism, endothelium. INTRODUCTION permeability by means of the generation of high electrochemical gradients. This action is performed by The hormone aldosterone was named after the aldehyde modulation of gene expression. group located on the carbon 18 of the steroidal skeleton which takes the place of the methyl group which Aldosterone synthase, the product of the CYP11B2 gene characterizes all the other steroidal compounds. It was and the final and rate-limiting enzyme of its synthetic isolated for the first time by Simpson and Tait in 1953 metabolic pathway, is expressed exclusively in the zona [1,2] and has since been characterized as the main glomerulosa, the outermost layer of the adrenal cortex, mineralocorticoid hormone in humans on the basis of its where it converts deoxycorticosterone to aldosterone by robust effects on the transepithelial unidirectional transport means of a three-step oxidative biochemical reaction [4,5]. of sodium [3]. Aldosterone action was originally believed to Its activity is regulated by the three main secretagogues of be limited to just few classical target organs, mainly of aldosterone, the plasma potassium concentration [6], the epithelial origin, where the hormone induced the activity of the renin-angiotensin system [7] and ACTH [8,9], biochemical modifications required to maintain volume and although many other compounds have been attributed a electrolyte homeostasis by acting through genomic minor role [10]. pathways. Nevertheless, in the last two decades a growing The genomic actions of aldosterone are mediated by its number of experimental observations has broadly expanded binding to the mineralocorticoid receptor (MR), a member of the limits of this classical model. In particular the spectrum the superfamily of ligand-regulated transcription factors. of tissues and organs involved in aldosterone action has This superfamily, featuring 49 members in humans [11] and turned out to be wider than previously expected and these including the receptors for the thyroid hormones, the retinoic targets (heart, blood vessels, brain) are now described as acid, the glucocorticoids and the sexual steroids, is made up “nonepithelial”. Moreover, aldosterone has been attributed of molecules which, in resting conditions, are localized in non-genomic effects, i.e. effects which do not depend on the the cytosol and that, following ligand binding, translocate to activation of the cellular transcription machinery. the nucleus to regulate gene expression. Further, its members CLASSICAL MOLECULAR PHYSIOLOGY OF display structural similarities, being composed of functionally ALDOSTERONE related distinct domains [12,13]: - a carboxy-terminal ligand binding domain (LBD) that Aldosterone has classically been described as a also binds heat shock proteins (HSPs) required to attain a mineralocorticoid hormone produced exclusively in the high affinity ligand-binding capacity [14], and is further adrenals and acting on a small number of epithelial target involved in receptor dimerization, nuclear targeting and organs (kidney, colon, salivary and sweat glands) exhibiting hormone-dependent transactivation; high electrical resistance and capable of regulating water - an amino-terminal domain, the most variable region within the steroid receptor superfamily, that has a ligand- *Address correspondence to this author at the Division of Internal Medicine independent transactivation function; and Hypertension, AOU San Giovanni Battista, Via Genova 3, 10126, Torino, Italy; Tel: -39-011-6336959; Fax: -39-011-6602707; - a highly conserved central DNA binding domain (DBD), E-mail: [email protected] involved in DNA binding and receptor dimerization; 1574-3624/12 $58.00+.00 ©2012 Bentham Science Publishers Genomic and Non-genomic Effects of Aldosterone Current Signal Transduction Therapy, 2012, Vol. 7, No. 2 133 - a hydrophilic hinge region between the DBD and the proteins, which are characterized by a single transmembrane LBD. domain and regulate the activity of pumps and ion transporters; it displays a 50% homology with the subunit Upon aldosterone binding, the HSPs dissociate from the + + of the Na /K -ATPase, is selectively expressed in the distal MR permitting the LBD to mediate the nuclear translocation parts of the nephron and in the epithelial cells of the distal [15,16] and the ensuing binding to specific hormone colon, and acts by increasing its affinity for the intracellular response elements in the promoter regions of target genes sodium; corticosteroid hormones, sodium restriction, low- [17]; the recruitment of the relevant transcription initiation potassium diet and metabolic acidosis have been shown to complex and coactivators or corepressors permits either to significantly up-regulate CHIF mRNA expression [32,33]. activate or repress gene transcription [18]. K-Ras is a monomeric GTPase whose activity stabilizes Since the cloning of the MR, its high sequence homology ENaC in the opening state [34]; it directly stimulates with the glucocorticoid receptor became evident [19]. This phosphoinositide 3-OH kinase (PI3K) to produce inositol homology is not limited to the DBD but also to the LBD and triphosphate which in turn acts onto the ENaC [35]. These determines a ten-fold higher affinity of cortisol for the MR data have shed light on previous observations regarding the compared to its own receptor [20]. Since cortisol circulates crucial role of PI3K for aldosterone to induce early and late at much higher concentrations than aldosterone, it would be effects on its epithelial target cells [36]. expected to preferentially occupy the MR: however, in the NON-GENOMIC EFFECTS epithelial target tissues of aldosterone and in some other tissues, aldosterone specificity is maintained by the action of Non-genomic effects are characterized by their short time the enzyme 11-hydroxysteroid dehydrogenase type 2 (11- lag of action, occurring in a few minutes or even seconds, HSD2) which converts cortisol to its inactive metabolite and their insensitivity to transcription and translation cortisone [21]. In case of genetic or pharmacological inhibitors. The first rapid non-genomic actions of aldosterone inactivation of this enzyme, the syndrome of apparent to be described date back to the sixties, when enhanced mineralocorticoid excess ensues, where the MR is constantly sodium exchange was reported in canine erythrocytes [37]. activated by circulating glucocorticoids [22]. Nevertheless, Later on, aldosterone was reported to trigger non-genomic other mechanisms that confer receptor activation specificity effects on a large number of cells types, most notably must exist in those tissues where 11-HSD2 has not been mononuclear leucocytes, endothelial cells, vascular smooth detected, such as hypothalamus and cardiomyocytes [23]. muscle cells (VSMC) and cardiomyocytes [38]. The first studies focused on the rapid modulation of the trans- The regulation of gene transcription in the classical membrane electrolyte transport consisting of a rapid and epithelial target organs occurs in a two step modality; in the transient increase in intracellular Ca2+ followed by activation early phase, which takes place in the first three hours from of the NHE [39,40]; the final effect consists in an increase in aldosterone stimulation, regulatory proteins of pre-existing cell volume that can be monitored by atomic force ion channels and transporters are modulated; in the second microscopy and intracellular alkalinization [41]. The one, new pumps, transporters and ion channels are directly intracellular metabolic pathways mediating these events rely produced with an increase in their density at the membrane on the c-Src dependent activation of EGFR and the ensuing level. These last molecules are considered the final effectors MAPK activation [42], although other authors have proposed of the mineralocorticoid action in epithelia and have been a role also for protein kinase C [43,44] and PI3K [45]. identified as the epithelial sodium channel (ENaC), acting on the luminal side, and the Na+/K+-ATPase, acting on the Debate still persists
Recommended publications
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Aldactone 50 mg Film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of Spironolactone. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet (Tablets) Round, white coloured, biconvex tablet with a peppermint odour embossed ‘SEARLE over 916’ on one side and the other side plain. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. Children should only be treated under guidance of a paediatric specialist. There is limited paediatric data available (see sections 5.1 and 5.2). 4.2 Posology and method of administration Administration of Aldactone once daily with a meal is recommended. Posology Adults Congestive heart failure: Usual dose - 100 mg/day. In difficult or severe cases the dosage may be gradually increased up to 200 mg/day. When oedema is controlled, the usual maintenance level is 75 mg/day to 200 mg/day. Severe heart failure in conjunction with standard therapy (New York Heart Association Class III-IV): Based on the Randomized Aldactone Evaluation Study (RALES), treatment in conjunction with standard therapy should be initiated at a dose of spironolactone 25 mg once daily in patients with a serum potassium ≤5.0 mEq/L and serum creatinine ≤2.5 mg/dL. Patients who tolerate 25 mg once daily may have their dose increased to 50 mg once daily as clinically indicated.
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • Australian Product Information – Aldactone® (Spironolactone)
    AUSTRALIAN PRODUCT INFORMATION – ALDACTONE® (SPIRONOLACTONE) 1. NAME OF THE MEDICINE Spironolactone 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The 25 mg ALDACTONE tablets contain 25 mg spironolactone. The 100 mg ALDACTONE tablets contain 100 mg spironolactone. For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Film-coated tablets. 25 mg ALDACTONE tablets: 8.7 mm in diameter, round, biconvex, buff coloured, peppermint flavoured, film coated, stamped SEARLE over 39 on one side and unmarked on the other. 100 mg ALDACTONE tablets: 11.2 mm in diameter, round, biconvex, buff coloured, peppermint flavoured, film coated, stamped SEARLE over 134 on one side and unmarked on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Essential Hypertension ALDACTONE, when used alone, is effective in lowering both systolic and diastolic blood pressure. ALDACTONE improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. ALDACTONE enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators, etc. Version: pfpaldat10621 Supersedes: pfpaldat10220 Page 1 of 12 As adjunctive therapy in malignant hypertension. In diuretic-induced hypokalaemia when other measures are considered inappropriate or inadequate. Prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Oedematous disorders, such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome. Congestive Cardiac Failure ALDACTONE, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. ALDACTONE may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Dosage and Administration
    HGDS"'FG ·-···--··-· ..---- ·---·' .. e ·--­··---····~·----- 133 Molesworth Street PO Box5013 Wellington 6140 New Zealand T +64 4 496 2000 1 February 2019 Response to your request for official information I refer to your request of 4 January 2019 to the Ministry of Health (the Ministry), under the Official Information Act 1982 (the Act), for. "I wish to request the following information regarding (the now lapsed) Aldactone, film coated tablets, spironolactone 25 mg and 100mg (TTS0-1764, 1764a): • Please provide a copy of the most recent datasheet (approved in a CMN or notified ina SACN). • Please provide a copy of the most recent primary and secondary labelling (approved in a CMN or notified in a SACN). • Please advise if the approved NZ labelling included an ARTG number." Information held by the Ministry relating to your request is itemised below, with copies of documents attached. Attachment Details and decision number - Data sheet for Aldactone 25 mg and Aldactone 100 mg. 1 Information released in full. Copy of the primary and secondary labelling for Aldactone 25 mg and 2 Aldactone 100 mg. Information released in full. In response to part three of your request, the Ministry confirms that the approved secondary labelling for Aldactone 25 mg and Aldactone 100 mg in New Zealand contained Australian Register of Therapeutic Goods (ARTG) numbers: AUST R 68953 (Aldactone 25 mg) and AUST R 68954 (Aldactone 100 mg). I trust this information fulfils your request. Please note this response (with your personal details removed) may be published on the Ministry of Health website. Yours si r;,c;:arely ~ r,,..~-~/___/ / /..
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Prestwick Collection
    (-) -Levobunolol hydrochloride (-)-Adenosine 3',5'-cyclic monophosphate (-)-Cinchonidine (-)-Eseroline fumarate salt (-)-Isoproterenol hydrochloride (-)-MK 801 hydrogen maleate (-)-Quinpirole hydrochloride (+) -Levobunolol hydrochloride (+)-Isoproterenol (+)-bitartrate salt (+,-)-Octopamine hydrochloride (+,-)-Synephrine (±)-Nipecotic acid (1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) (cis-) Nanophine (d,l)-Tetrahydroberberine (R) -Naproxen sodium salt (R)-(+)-Atenolol (R)-Propranolol hydrochloride (S)-(-)-Atenolol (S)-(-)-Cycloserine (S)-propranolol hydrochloride 2-Aminobenzenesulfonamide 2-Chloropyrazine 3-Acetamidocoumarin 3-Acetylcoumarin 3-alpha-Hydroxy-5-beta-androstan-17-one 6-Furfurylaminopurine 6-Hydroxytropinone Acacetin Acebutolol hydrochloride Aceclofenac Acemetacin Acenocoumarol Acetaminophen Acetazolamide Acetohexamide Acetopromazine maleate salt Acetylsalicylsalicylic acid Aconitine Acyclovir Adamantamine fumarate Adenosine 5'-monophosphate monohydrate Adiphenine hydrochloride Adrenosterone Ajmalicine hydrochloride Ajmaline Albendazole Alclometasone dipropionate Alcuronium chloride Alexidine dihydrochloride Alfadolone acetate Alfaxalone Alfuzosin hydrochloride Allantoin alpha-Santonin Alprenolol hydrochloride Alprostadil Althiazide Altretamine Alverine citrate salt Ambroxol hydrochloride Amethopterin (R,S) Amidopyrine Amikacin hydrate Amiloride hydrochloride dihydrate Aminocaproic acid Aminohippuric acid Aminophylline Aminopurine, 6-benzyl Amiodarone hydrochloride Amiprilose hydrochloride Amitryptiline hydrochloride
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,684,635 Orentreich Et Al
    United States Patent (19) 11 Patent Number: 4,684,635 Orentreich et al. (45) Date of Patent: Aug. 4, 1987 54: COMPOSITIONS AND METHODS FOR N. Orentreich et al., "Biology of Scaly Hair Growth," INHIBITING THE ACTION OF ANDROGENS 9 Clinics in Plastic Surgery (1982), 197-205. R. Aron-Brunetiere, "Aspects of Endocrinological 75 Inventors: Norman Orentreich, 140 E. 72, New Treatment," Hair Research (1981), 312-317. York, N.Y. 10021; Jonathan R. J. R. Rentoul, "Management of the Hirsuite Woman," Matias, Richmond Hill, N.Y. 22 Int'l J. of Derm. (1983), 265-272. 73) Assignee: Norman Orentreich, New York, N.Y. P. G. Nielsen, "Treatment of Moderate Idiopathic Hir sutism,' 165 Dermatologica (1982), 636-639. 21) Appl. No.: 846,498 F. Neuman et al., "Central Actions of Antiandrogens,' Androgens and Antiandrogens (1977), 163-177. 22 Filed: Mar. 27, 1986 F. J. Ebling, "Antiandrogens and Dermatology,” An drogens and Antiandrogens (1977), 341-349. Related U.S. Application Data W. I. P. Mainwaring, “Modes of Action of Antiandro I63) Continuation of Ser. No. 609,152, May 11, 1984, aban gens,' Androgens and Antiandrogens (1977), 151-161. doned. J. P. Raynaud et al., "Present Trends in Antiandrogen 51) Int. Cl............................................... A61K 31/56 Research,” Androgens and Antiandrogens (1977), 52 U.S. Cl. .................................... 514/170; 514/171; 28-293. 514/175; 514/177; 514/178 A. L. Southren et al., "Effect of Progestagens,' Andro 58) Field of Search ............... 514/177, 178, 170, 171, gens and Antiandrogens (1977), 267-279. 514/175 Primary Examiner-Leonard Schenkman Attorney, Agent, or Firm-Panitch Schwarze Jacobs and (56) References Cited Nadel U.S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]